Diffusion Pharmaceuticals DFFN shares are trading lower on Monday after the company received guidance from the FDA on the company's IND for trans sodium crocetinate in Covid-19 patients.
Diffusion Pharmaceuticals is a clinical stage biotechnology company. It is focused on extending the life expectancy of cancer patients by improving the effectiveness of current standard-of-care treatments, including radiation therapy and chemotherapy.
The company's lead product candidate is trans sodium crocetinate (TSC), which is used for the treatment of glioblastoma multiforme (GBM); Phase II pancreatic cancer; and metastatic brain cancer. Geographically business activity of the firm is functioned through the region of the US.
Diffusion Pharmaceuticals shares were down 14.39% at $1.13 on Monday. The stock has a 52-week range between $2.42 and 21 cents.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
